Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.66 |
| ▸ | RXRA | P19793 | 7/20 | 0.66 |
| ▸ | RARA | P10276 | 6/20 | 0.66 |
| ▸ | RARB | P10826 | 6/20 | 0.66 |
| ▸ | RARG | P13631 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.66 |
| ▸ | RXRB | P28702 | 3/20 | 0.66 |
| ▸ | RXRG | P48443 | 3/20 | 0.66 |
| ▸ | RORC | P51449 | 2/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | HTR2B | P41595 | 2/20 | 0.66 |
| ▸ | BLM | P54132 | 2/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.66 |
| ▸ | DRD3 | P35462 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15609136 | 1.00 | CYP1A2 (1.00) | CYP1A2HAO1ALDH1A1RXRARARA | |
| SCHEMBL954746 | 1.00 | CYP1A2 (1.00) | CYP1A2HAO1ALDH1A1RXRARARA | |
| SCHEMBL11790962 | 0.87 | ALDH1A1 (0.85) | CYP1A2HAO1ALDH1A1RXRARARA | |
| SCHEMBL8776466 | 0.87 | ALDH1A1 (0.85) | CYP1A2HAO1ALDH1A1RXRARARA | |
| SCHEMBL8016155 | 0.87 | CYP1A2 (0.77) | CYP1A2HAO1ALDH1A1RXRARARA | |
| SCHEMBL2509310 | 0.87 | CYP1A2 (0.77) | CYP1A2HAO1ALDH1A1RXRARARA | |
| SCHEMBL8975766 | 0.87 | ALDH1A1 (0.85) | CYP1A2HAO1ALDH1A1RXRARARA | |
| SCHEMBL2509311 | 0.87 | CYP1A2 (0.77) | CYP1A2HAO1ALDH1A1RXRARARA | |
| SCHEMBL8012505 | 0.87 | CYP1A2 (0.77) | CYP1A2HAO1ALDH1A1RXRARARA | |
| SCHEMBL4823499 | 0.87 | CYP1A2 (0.76) | CYP1A2ALDH1A1RXRARARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013700-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-05-25 | — | — | US | disclosed |
| US-10980835-B2 | Arsenic trioxide for treatment of PIN1-associated disorders | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200129453-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2020-04-30 | — | — | US | disclosed |
| US-10548864-B2 | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10363231-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-07-30 | — | — | US | disclosed |
| EP-3100723-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10265288-B2 | Methods and compositions for the treatment of proliferative disorders | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180153934-A1 | ARSENIC TRIOXIDE FOR TREATMENT OF PIN1-ASSOCIATED DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-07 | — | — | US | disclosed |
| US-20180064666-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20170340581-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2017-11-30 | — | — | US | disclosed |
| US-20080200478-A1 | ANTINEOPLASTIC AND CURCUMIN DERIVATIVES AND METHODS OF PREPARATION AND USE | ROBINSON BYRON C | 2008-08-21 | — | — | US | disclosed |
| US-20080200478-A1 | ANTINEOPLASTIC AND CURCUMIN DERIVATIVES AND METHODS OF PREPARATION AND USE | ROBINSON BYRON C | 2008-08-21 | — | — | US | disclosed |
| US-20080200478-A1 | ANTINEOPLASTIC AND CURCUMIN DERIVATIVES AND METHODS OF PREPARATION AND USE | ROBINSON BYRON C | 2008-08-21 | — | — | US | disclosed |
| EP-1889837-A1 | VR1 vanilloid receptor antagonists with a iononic substructure | Pharmeste S.r.l. (IT) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008006481-A1 | VR1 VANILLOID RECEPTOR ANTAGONISTS WITH A IONONIC SUBSTRUCTURE | PHARMESTE S.R.L. (IT) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007098118-A9 | ANTINEOPLASTIC AND CURCUMIN DERIVATIVES AND METHODS OF PREPARATION AND USE | BYRON ROBINSON PHARMACEUTICAL (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007098118-A9 | ANTINEOPLASTIC AND CURCUMIN DERIVATIVES AND METHODS OF PREPARATION AND USE | BYRON ROBINSON PHARMACEUTICAL (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007098118-A2 | ANTINEOPLASTIC AND CURCUMIN DERIVATIVES AND METHODS OF PREPARATION AND USE | BYRON ROBINSON PHARMACEUTICAL, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007098118-A2 | ANTINEOPLASTIC AND CURCUMIN DERIVATIVES AND METHODS OF PREPARATION AND USE | BYRON ROBINSON PHARMACEUTICAL, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| EP-1442014-B1 | MANUFACTURE OF RETINOIDS | DSM IP ASSETS BV (NL) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129453-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, ADH1B, ADCYAP1R1 | CYP1A2 972/4885HAO1 2252/4885ALDH1A1 203/4885 |
| US-20170340581-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, ADH1B, ADCYAP1R1 | CYP1A2 1057/4885HAO1 2187/4885ALDH1A1 198/4885 |
| US-10980835-B2 | Arsenic trioxide for treatment of PIN1-associated disorders | PIN1, AS3MT, PML | CYP1A2 3211/4885HAO1 3071/4885ALDH1A1 2657/4885 |
| US-20180153934-A1 | ARSENIC TRIOXIDE FOR TREATMENT OF PIN1-ASSOCIATED DISORDERS | PIN1, AS3MT, PML | CYP1A2 3211/4885HAO1 3071/4885ALDH1A1 2657/4885 |
| US-20080200478-A1 | ANTINEOPLASTIC AND CURCUMIN DERIVATIVES AND METHODS OF PREPARATION AND USE | BCL3, CASP3, MCL1 | CYP1A2 617/4885HAO1 2107/4885ALDH1A1 361/4885 |
| US-10548864-B2 | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions | PIN1, RARB, RARA | CYP1A2 2871/4885HAO1 3438/4885ALDH1A1 1735/4885 |
| US-10363231-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, ADH1B, ADCYAP1R1 | CYP1A2 1057/4885HAO1 2187/4885ALDH1A1 198/4885 |
| US-20180064666-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | PIN1, RARB, RARA | CYP1A2 2871/4885HAO1 3438/4885ALDH1A1 1735/4885 |
| US-11013700-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, ADH1B, ADCYAP1R1 | CYP1A2 972/4885HAO1 2252/4885ALDH1A1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.